New functionalized cholesterol molecules comprising cholesterol backbone and functional group attached to 3beta-hydroxy, for preparing particulate pharmaceutical formulation, system for delivering therapeutic agents e.g. genetic materials for treating genetic disorders, used in e.g. gene silencing
2023-09-21
专利权人BIRLA INST TECHNOLOGY & SCI PILANI (BIRL-Non-standard)
申请日期2023-09-21
专利号IN202311019415-A
成果简介NOVELTY - Functionalized cholesterol molecules comprising a cholesterol backbone; and a functional group attached to the 3β-OH of the cholesterol backbone is new. USE - Functionalized cholesterol molecules for preparing particulate pharmaceutical formulation and system for delivering therapeutic agents such as genetic materials, peptides, proteins, and ribonucleoproteins for treating genetic disorders (all claimed); used in gene silencing, gene expression modulation, or gene editing. No biological data given. ADVANTAGE - The molecule improves interaction with cell membranes and enhances the efficacy of the drug delivery. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: a particulate pharmaceutical formulation comprises the functionalized cholesterol molecules and a therapeutic agent, where the formulation delivering therapeutic agents selected from genetic materials, peptides, proteins, and ribonucleoproteins; and a pharmaceutical carrier system comprising at least one functionalized cholesterol molecule.
IPC 分类号A61K-031/70 ; A61K-047/00 ; C07C-229/00
国家印度
专业领域医药卫生
语种英语
成果类型专利
文献类型科技成果
条目标识符http://119.78.100.226:8889/handle/3KE4DYBR/20298
专题中国科学院新疆生态与地理研究所
作者单位
BIRLA INST TECHNOLOGY & SCI PILANI (BIRL-Non-standard)
推荐引用方式
GB/T 7714
MITTAL A,ANSARI I,CHITKARA D. New functionalized cholesterol molecules comprising cholesterol backbone and functional group attached to 3beta-hydroxy, for preparing particulate pharmaceutical formulation, system for delivering therapeutic agents e.g. genetic materials for treating genetic disorders, used in e.g. gene silencing. IN202311019415-A[P]. 2023.
条目包含的文件
条目无相关文件。
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。